---
document_datetime: 2024-04-30 17:08:59
document_pages: 28
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/mirapexin-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: mirapexin-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 50.8663283
conversion_datetime: 2025-12-20 13:58:05.06732
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Mirapexin

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                               | Opinion/ Notification 1 issued on   | Commission Decision IssuedÂ² / amended on   | Product Information affected3    | Summary   |
|----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|--------------------------------------------|----------------------------------|-----------|
| WS/2626              | This was an application for a variation following a worksharingprocedureaccordingtoArticle20of CommissionRegulation(EC)No1234/2008. Updateofsection4.8oftheSmPCto add 'spontaneouspenileerection'tothelistofadverse | 14/03/2024                          |                                            | SmPC, Annex II, Labelling and PL |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions areissuedfor all otherprocedures.

3SmPC(Summary ofProductCharacteristics),AnnexII, Labelling,PL(PackageLeaflet).

2A Commission decision(CD) is issued for procedures that affect the terms of the marketing authorisation(e.g.summary of product characteristics, annexII, labelling,package leaflet).The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation(EU) No. 712/2012, or within one year for other procedures.

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                    | drugreactions(ADRs)with frequency`rare',based ontheoutcomeofacumulativereviewofdatafrom clinical, literature and post-marketing sources.The Package Leaflet (PL) is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the PL, introduce minor editorial changes to the product information (PI) and bring it in line with the updated QRD template version 10.3. C.I.4 -Change(s)in the SPC, Labelling or PL due to newquality,preclinical,clinical orpharmacovigilance data   |            |            |             |                                                                                                                                       |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/2491/ 202304 | Periodic Safety Update EU Single assessment - pramipexole                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 09/11/2023 | 05/01/2024 | SmPC and PL | Refer to Scientific conclusions and grounds recommending thevariation to terms of theMarketingAuthorisation(s)'for PSUSA/2491/202304. |
| IG/1657/G          | This was an application for a group of variations. A.7-Administrative change-Deletion of manufacturing sites A.5.b - Administrative change - Change in the name and/oraddressofamanufacturer/importerofthe finished product,including quality control sites (excludingmanufacturerforbatchrelease)                                                                                                                                                                                                                                         | 04/09/2023 | n/a        |             |                                                                                                                                       |
| WS/2399/G          | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.                                                                                                                                                                                                                                                                                                                                                                                    | 08/06/2023 | 05/01/2024 | PL          |                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| B.II.b.1.a-Replacement or addition of a manufacturing site for the Fp - Secondary packaging site B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation A.7-Administrativechange-Deletionof manufacturing sites B.II.b.5.z-Change to in-process tests or limits applied during the manufacture of the finished product - Other variation B.II.d.1.d-Change in the specification parameters and/orlimitsofthefinishedproduct-Deletionofa non-significantspecificationparameter B.II.b.4.a-Change inthebatchsize(includingbatch sizeranges)of the finishedproduct-Upto10-fold compared to the originally approved batch size B.II.b.3.a-Change in the manufacturingprocess of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.a-Change in the manufacturingprocess of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.a-Change in the manufacturing process of the finished or intermediate product - Minor change inthemanufacturingprocess B.II.b.2.c.2-Change to importer,batch release arrangements and quality control testing of the FP - Including batch control/testing B.II.b.3.a-Change in the manufacturing process of the finished or intermediate product - Minor change inthemanufacturingprocess   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                    | manufacturing site for the Fp - Primary packaging site B.II.b.1.e-Replacement or addition of a manufacturingsitefortheFP-Sitewhereany manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging,fornon-sterilemedicinalproducts   |            |            |                                  |                                |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|--------------------------------|
| WS/2352            | This was an application for a variation following a worksharingprocedure according toArticle20of CommissionRegulation(EC)No1234/2008. B.II.b.3.z-Change in the manufacturing process of thefinished orintermediateproduct-Othervariation                                             | 15/12/2022 | n/a        |                                  |                                |
| PSUSA/2491/ 202204 | Periodic Safety Update EU Single assessment - pramipexole                                                                                                                                                                                                                            | 01/12/2022 | n/a        |                                  | PRACRecommendation-maintenance |
| WS/2169            | This was an application for a variation following a worksharingprocedure according toArticle20of CommissionRegulation(EC)No1234/2008. C.I.z-Changes(Safety/Efficacy)of Human and VeterinaryMedicinalProducts-Othervariation                                                          | 16/12/2021 | 09/01/2023 | SmPC, Annex II, Labelling and PL |                                |
| N/0100             | Minor change in labelling or package leaflet not connectedwiththeSPC(Art.61.3Notification)                                                                                                                                                                                           | 08/09/2021 | 19/10/2021 | PL                               |                                |
| IG/1334            | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                         | 26/03/2021 | n/a        |                                  |                                |

<div style=\"page-break-after: always\"></div>

| WS/1897            | This was an application for a variation following a worksharing procedure according to Article 20 of CommissionRegulation(EC)No1234/2008. C.1.11.z-Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation,including the RMP-Other variation                                                                                      | 29/10/2020   | n/a        |                 |                                                                                                                                         |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------|
| IG/1289/G          | Thiswasanapplicationforagroupofvariations. B.II.b.1.a-Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacementoradditionofamanufacturer responsibleforimportationand/orbatchrelease- Not including batch control/testing | 16/10/2020   | 19/10/2021 | Annex II and PL |                                                                                                                                         |
| IG/1281            | B.IIl.1.a.1-Submission of a new/updated or deletionofPh.Eur.CertificateofSuitabilityto the relevant Ph. Eur. Monograph - New certificate from analreadyapprovedmanufacturer                                                                                                                                                                                             | 25/08/2020   | n/a        |                 |                                                                                                                                         |
| PSUSA/2491/ 201904 | PeriodicSafetyUpdateEUSingle assessment- pramipexole                                                                                                                                                                                                                                                                                                                    | 12/12/2019   | 21/02/2020 | SmPC and PL     | Refer to Scientific conclusions and grounds recommending the variation to terms of theMarketing Authorisation(s)'for PSUSA/2491/201904. |
| IG/1198            | A.5.b-Administrative change-Change in the name and/oraddressofamanufacturer/importerofthe finishedproduct,including quality control sites                                                                                                                                                                                                                               | 24/01/2020   | n/a        |                 |                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

|           | (excluding manufacturer for batch release)                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |            |            |                        |                                                 |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------------------|
| IG/1176   | B.IIl.1.a.1-Submission of a new/updated or deletionofPh.Eur.CertificateofSuitability tothe relevant Ph.Eur.Monograph-New certificate from analreadyapprovedmanufacturer                                                                                                                                                                                                                                                                                                                                             | 12/12/2019 | n/a        |                        |                                                 |
| WS/1672   | This was an application for a variation following a worksharingprocedureaccordingtoArticle20of CommissionRegulation(EC)No1234/2008. C.I.7.b-Deletion of-a strength                                                                                                                                                                                                                                                                                                                                                  | 12/09/2019 | 21/02/2020 | SmPC, Labelling and PL |                                                 |
|           | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.d.1.g -Change in the specification parameters and/or limits of the finished product - Addition or replacement (excluding biological or immunological product)ofaspecificationparameterwit its correspondingtestmethodasaresultofasafety or qualityissue C.I.13-Othervariationsnotspecifically covered elsewherein thisAnnexwhich involve thesubmission | 12/09/2019 | n/a        |                        | WS/1647/G of studies to the competent authority |
| WS/1631/G | Thiswasanapplicationforagroupofvariations following a worksharing procedure according to Article20ofCommissionRegulation(EC)No                                                                                                                                                                                                                                                                                                                                                                                      | 25/07/2019 | 21/02/2020 | Annex II and PL        |                                                 |

<div style=\"page-break-after: always\"></div>

|         | 1234/2008. A.7-Administrative change-Deletion of manufacturing sites B.II.b.1.a - Replacement or addition of a manufacturing site for the Fp-Secondary packaging site B.II.b.1.b-Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.1.e -Replacement or addition of a manufacturing site for the FP - Site where any manufacturingoperation(s)takeplace,exceptbatch- release, batch control, primary and secondary packaging, for non-sterile medicinal products B.II.b.2.c.2-Change to importer,batch release arrangements and quality control testing of the FP - Including batch control/testing B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.a-Change in the manufacturingprocess of the finished or intermediate product - Minor change in themanufacturingprocess B.II.b.4.b -Change in the batch size (including batch sizeranges)of thefinishedproduct-Downscaling   |            |     |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| WS/1510 | This was an application for a variation following a worksharing procedure according to Article 20 of CommissionRegulation(EC)No1234/2008.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 11/04/2019 | n/a |

<div style=\"page-break-after: always\"></div>

|         | To introduce RMP version 10.0, the RMP has been converted intothenewRMPtemplateasperGVP Module VRevision2(EMA/838713/2011Rev2).In addition, the applicant takes the opportunity to adapt themedicalsearchstrategiesanddataretrieval approach without any impact on the overall safety conclusion. C.I.11.b -Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation,including theRMP-Implementation of change(s)whichrequiretobefurthersubstantiated bynewadditionaldatatobesubmittedbytheMAH wheresignificantassessmentisrequired   |            |            |                  |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------|
| IG/1033 | A.5.b-Administrative change-Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excludingmanufacturerforbatchrelease)                                                                                                                                                                                                                                                                                                                                                                                   | 14/12/2018 | n/a        |                  |
| N/0087  | Minor changeinlabellingorpackageleafletnot connectedwiththeSPC(Art.61.3Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 20/06/2018 | 06/02/2019 | Labelling and PL |
| WS/1318 | Thiswas an applicationfor avariationfollowing a worksharingprocedure according toArticle20 of CommissionRegulation(EC)No1234/2008. C.I.z - Changes (Safety/Efficacy) of Human and VeterinaryMedicinalProducts-Othervariation                                                                                                                                                                                                                                                                                                                                               | 08/02/2018 | 06/02/2019 | SmPC andPL       |

<div style=\"page-break-after: always\"></div>

| PSUSA/2491/ 201604   | Periodic Safety Update EU Single assessment - pramipexole                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 15/12/2016   | 16/02/2017   | SmPC and PL                      | Refer to Scientific conclusions and grounds recommending thevariationtotermsof theMarketingAuthorisation(s)'for PSUSA/2491/201604.                                                                                       |
|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0909              | This was an application for a variation following a worksharing procedure according to Article 20 of CommissionRegulation(EC)No1234/2008. Updateofsection4.4oftheSmPCinordertoadda precautionarystatementpertainingtothepotential occurrenceof'remnantsinstool'fortheprolonged- releasetabletformulation.ThePackageLeafletis updated accordingly. In addition, the Worksharing applicant(wSA)tooktheopportunitytoupdatethe list of local representatives for Portugal and Spain in thePackageLeaflet and tobring thePIinlinewith the latest QRD template version 9.1. Furthermore, the worksharing applicant took the opportunity to correctmistakesmade during implementation of QRDv.8.0andtocorrectlinguisticmistakeinthe Estonian product information. C.I.4 -Change(s)in the SPC, Labelling or PL due to newquality,preclinical,clinical orpharmacovigilance data | 01/04/2016   | 16/02/2017   | SmPC, Annex II, Labelling and PL | Somepatientshavereportedtheoccurrenceofremnantsin faeces which may resemble intact pramipexole prolonged- releasetablets.Ifpatientsreportsuch anobservation,the physician should reassess patient's response to therapy. |
| IG/0607              | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excludingmanufacturerforbatchrelease)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 16/10/2015   | n/a          |                                  |                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

| IG/0605/G   | This was an applicationfor a groupofvariations.                                                                                                                                                                                                                                                                                                                                                                                                                                               | 16/10/2015   | n/a        |                       |           |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------------|-----------|
|             | Thiswas an applicationfor a groupof variations. A.5.b - Administrative change - Change in the name and/oraddressofamanufacturer/importerofthe finished product, including quality control sites (excludingmanufacturerforbatchrelease) A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excludingmanufacturerforbatchrelease) A.7-Administrative change-Deletion of manufacturing sites | 16/10/2015   | n/a        |                       | IG/0606/G |
| WS/0648     | Thiswasanapplicationforavariationfollowinga worksharingprocedureaccordingtoArticle20of CommissionRegulation(EC)No1234/2008. C.I.z - Changes (Safety/Efficacy) of Human and VeterinaryMedicinalProducts-Othervariation                                                                                                                                                                                                                                                                         | 23/10/2014   | 08/10/2015 | SmPC, Annex II and PL |           |

<div style=\"page-break-after: always\"></div>

| IG/0432            | C.I.8.a-Introductionof or changestoasummary of Pharmacovigilance system - Changes in QPPV (includingcontactdetails)and/orchangesinthe PSMFlocation                                                                                                                                                                                                                                                                                                                                                                         | 16/04/2014   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0417            | B.II.b.2.a-Change to importer,batch release arrangements and quality control testing of the FP - Replacement/additionofasitewherebatch control/testingtakesplace                                                                                                                                                                                                                                                                                                                                                           | 14/03/2014   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| PSUSA/2491/ 201304 | Periodic Safety Update EU Single assessment - pramipexole                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 18/12/2013   | 28/02/2014 | SmPC and PL | RefertoScientificconclusionsandgroundsrecommending thevariation toterms of theMarketingAuthorisation(s)'for PSUSA/2491/201304.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| N/0076             | Minor change inlabelling orpackageleaflet not connected with theSPC(Art.61.3Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                  | 03/07/2013   | 28/02/2014 | PL          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| WS/0326            | This was an application for a variation following a worksharingprocedureaccordingtoArticle20of CommissionRegulation(EC)No1234/2008. Update of SmPCsections 4.4and4.8inorder to update the safety information by implementing class labellingfortheriskof impulsecontrol disorders. C.1.3.a - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR,RMP,FUM/SO,datasubmittedunderA45/46, or amendments toreflectaCoreSPC-Changeswith NOnewadditionaldata aresubmitted by theMAH | 15/11/2012   | 30/11/2012 | SmPC and PL | Based on a recent review of the available post-marketing datainrelationtotheriskofdevelopmentofimpulse control disorders when using medicinal products containing levodopa,dopamineagonists and/orCatechol-O- methyltransferase(COMT)inhibitors,the CHMP/PhVWP recommendedaclasslabellingtoupdate andharmonise theproductinformationofrelevantproductstoreflect relatedbehaviouralsymptomsincludingcompulsive spending or buying, binge eating and compulsive eating andthattheadversereactioncanoccurirrespectiveofthe indication and at normal doses.The classlabelling also provided for regular monitoring of patients and harmonised wordingforacarefulreviewoftreatmentifsymptoms occur. The Package Leaflet was updated in accordance and additionaladviceforthepatient'sfamilyandcarerswas |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |            |                                  | provided.                                                                                                                                                                                                                                                                                                                                                   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0311   | Thiswas an applicationfor avariationfollowing a worksharing procedure according to Article 20 of CommissionRegulation(EC)No1234/2008. Updateofsection4.8oftheSmPCinordertoinclude inappropriate antidiuretic hormone secretion as an adversedrugreactionbasedonpost-marketingdata. ThePackageLeafletisupdatedinaccordance. Furthermoreamoredetaileddescriptionoftheouter appearance of the immediate release tablets was included in thePackageLeaflet. In addition, editorial changes were made and the list of local representatives for Latvia was updated. Furthermore,theProductInformationwasbrought in line with the latest QRD template version 8.0. C.I.4-Variations related to significant modifications of theSPCdueinparticulartonewquality,pre- | 18/10/2012 | 19/11/2012 | SmPC, Annex II, Labelling and PL | Acumulativereviewofpost-marketingreportsshowed an increased number of cases of inappropriate antidiuretic hormone secretion in recent years. As a causal relationship between the use of pramipexole and development of inappropriate antidiuretic hormone secretion could not be excluded,it was included as anadversereaction in the product information. |
| IG/0211   | C.I.z - Changes (Safety/Efficacy) of Human and VeterinaryMedicinalProducts-Othervariation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 05/09/2012 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                             |
| WS/0255/G | Thiswasanapplicationforagroupofvariations following a worksharing procedure according to Article20ofCommissionRegulation(EC)No 1234/2008. Update of the Description of Pharmacovigilance System (DDPS).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 24/05/2012 | 24/05/2012 |                                  | Changes to an existing pharmacovigilance system as describedintheDDPS.TheMAHupdatetheDetailed DescriptionofthePharmacovigilanceSystem(DDPS)for Aptivus, MicardisPlus, Mirapexin, Onduarp, Pradaxa, Sifrol, Trajenta, Twynsta and Viramune.                                                                                                                  |

<div style=\"page-break-after: always\"></div>

|           | C.I.9.z-Changes to an existingpharmacovigilance system as described in the DDPS - Other variation C.I.9.z - Changes to an existing pharmacovigilance system as described in the DDPS -Other variation C.I.9.f - Changes to an existing pharmacovigilance system as described in the DDPS -Deletion of topics covered by written procedure(s) describing pharmacovigilance activities C.I.9.d-Changes to an existing pharmacovigilance system as described in the DDPS - Change in the safety database C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the back-upprocedureoftheQPPV C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) totheDDPSthatdoesnotimpactontheoperationof the pharmacovigilance system   |            |            |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|
| WS/0134/G | This was an application for a group of variations following a worksharing procedure according to Article20of CommissionRegulation(EC)No 1234/2008. Changeinthespecificationofthefinishedproductto replace the test Uniformity of Content (Ph Eur 2.9.6) with Uniformity of Dosage Units (Ph Eur 2.9.40). Minor changeintheHPLCmethod usedfor assay/content and uniformity of dosage units to improve the process descriptions by adding holding                                                                                                                                                                                                                                                                                                                                                                   | 23/06/2011 | 23/06/2011 |

<div style=\"page-break-after: always\"></div>

|         | timesforthestandard and testsolutions. B.II.d.1.z-Change in the specification parameters and/orlimits of thefinishedproduct-Othervariation B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                     |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0133 | This was an application for a variation following a worksharingprocedureaccordingtoArticle20of CommissionRegulation(EC)No1234/2008. Extensionof thebulkproductholding timefor 0.18 mg, 0.35 mg and 0.7 mg tablets. B.II.b.3.z-Change in the manufacturing process of thefinishedproduct-Othervariation                                                                                                                                                                                                                      | 23/06/2011 | 23/06/2011 |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| WS/0128 | This was an application for a variation following a worksharingprocedureaccordingtoArticle20of CommissionRegulation(EC)No1234/2008. Updateofsection4.8toinclude'cardiacfailure'as a new side effect. In addition, information has been addedtosection4.8abouttheestimationof frequenciesforlistedsideeffectsobservedpost marketing.The PL hasbeen updated accordingly. C.I.4-Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data | 19/05/2011 | 17/06/2011 | SmPC and PL | Based on an analysis of safety data and recent findings from a pharmacoepidemiological study, the MAH proposes toinclude'cardiacfailure'asanewsideeffectinsection 4.8of theSmPC.In addition,thefrequencies of listed side effectsobservedpostmarketinghavebeencalculated accordingtotheguidanceinthecurrentversionofthe SmPCguideline.Thefrequenciesforthesesideeffects remainunchangedcomparedwiththecurrentSmPC.The PL has been amended accordingly. |

<div style=\"page-break-after: always\"></div>

| WS/0101   | This was an application for a variation following a worksharing procedure according to Article 20 of CommissionRegulation(EC)No1234/2008. Extensionofshelf-lifeofthefinishedproduct (prolonged-release tablets)from2years to3years. B.II.f.1.b.1-Stability of FP-Extension of the shelf lifeof thefinishedproduct-Aspackagedforsale (supported by real time data)                                                                                                                                                                                                                                                  | 17/02/2011   | 18/03/2011   | SmPC              |                                                                                                                                                                                                                                                                                                                                                                                                            |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0061   | This was an application for a variation following a worksharingprocedure according toArticle20of CommissionRegulation(EC)No1234/2008. Update of Section 5.3 of SPC to include non-clinical informationconcerningdelayedsexualdevelopment observedinratsasagreedintheassessmentofFUM 040 (Sifrol) / 038 (Mirapexin). In addition, the MAH correctedminor errors in theEnglishversion of Annex I and Annex II and in Annexes I, II and IIIB of the Danish translation. C.1.3.a-Implementation of change(s)requested following the assessment of an USR, class labelling, a PSUR,RMP,FUM/SO,datasubmittedunderA45/46, | 18/11/2010   | 20/12/2010   | SmPC and Annex II | InFUM040(Sifrol)/FUM038(Mirapexin)theMAH submitted the final study reportsfor a clinical trial (248.642)andanon-clinicalstudy(U09-1156).In the assessmentofthesereportstheCHMPconcludedthatthe MAHshouldsubmit avariationapplication toinclude informationonadelayedsexualdevelopmentobservedin rats. With this procedure the MAH subsequently updated section5.3oftheSPCtoincludetherequestedinformation. |
| N/0065    | The MarketingAuthorisationHolder(MAH)took the                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 10/12/2010   | n/a          | PL                |                                                                                                                                                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|           | opportunity to update details of the local representatives in AnnexIIIB. Minor change in labelling or package leaflet not connected with the SPC(Art.61.3 Notification)                                                                                                                                                                                                                                                                           |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0042   | This was an application for a variation following a worksharing procedure according to Article 20 of CommissionRegulation(EC)No1234/2008. Toupdatesection4.2of theSPCwithspecific informationonmisseddosebasedonnewdata.The PL is updated accordingly. C.I.4-Variationsrelatedto significant modifications of theSPCdueinparticular to newquality,pre- clinical, clinical or pharmacovigilance data                                               | 23/09/2010 | 25/10/2010 | SmPC and PL | TheMAHperformedasimulationof thepramipexole plasmaconcentrationafter aninadvertentlymisseddoseof pramipexole prolonged-release tablets. Based on this analysis the product information is revised to include specificinformationonmisseddoseinsection4.2of the SPCandsection3oftheasfollows:\"Whentheintakeofa doseismissed,Sifrolprolonged-releasetabletsshouldbe taken within12 hours after the regularly scheduled time. After12hours,themissed dose should beleftout and the nextdoseshouldbetakenonthefollowing day at thenext regularly scheduled time.\"Part3of thePackageLeaflet was updated accordingly.                                                 |
| WS/0041/G | This was an application for a group of variations followingaworksharingprocedureaccording to Article20of CommissionRegulation(EC)No 1234/2008. Updateof thesection4.5oftheSPCtoincludethe resultsof anevaluation of hOcT2inhibitors andof section4.8of theSPCtoincludenewsideeffects andrevisefrequencycategoriesbasedondata submittedwithPSUR13.ThePackageLeaflethas been updated accordingly. C.I.4-Variationsrelatedtosignificantmodifications | 23/09/2010 | 25/10/2010 | SmPC and PL | In the assessment of line extension procedure EMEA/H/C/133,134/X/51,59,theCHMPrequestedthatthe MAHshouldperformsanindepthevaluationofhocT2 inhibitorswhichmaypotentiallyinterferewiththeactive tubularsecretion ofpramipexole.Following theassessment of thisevaluationtheCHMPrecommended thatsection4.5 of theSPCshouldbe amended toincludezidovudine, cisplatin, quinine, and procainamide. Furthermore,basedonthedataprovidedinPSuRNo.13a revisionof theProductInformationwasproposedbythe MAHï¼includingtheidentificationofnewsideeffects (hiccups, diplopia and decreased appetite), an adaptation to the revised MedDRA terminology and changes of several |

<div style=\"page-break-after: always\"></div>

|         | of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data C.I.3.a - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP,FUM/SO, data submitted under A 45/46, or amendments toreflectaCoreSPC-Changes with NOnewadditionaldataaresubmittedbytheMAH                                                                    |            |            |             | frequency categories.TheCHMPconsidered theproposed changestobeinlinewith theassessmentofPSUR13 and accepted theproposedchanges.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0064 | UpdateoftheSummaryofProductCharacteristcs (SPC)toincludethenegativeresultsofastudyin children and adolescents (age 6-17) diagnosed with Tourette'sDisorderandtherecommendationfornot using Mirapexin in children or adolescents with Tourette'sDisorder. C.I.4-Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data | 20/05/2010 | 01/07/2010 | SmPC        | Withthisvariationapplication theMAHsubmitted the results of a 6-week placebo-controlled study in 63 children and adolescents aged6-17years(inclusive)withTourette's Disorderinwhichtheefficacy andsafetyoffivedifferent total daily doses ofpramipexole(0.0625,0.125,0.25, 0.375 and 0.5 mg) were administered. The primary endpointinthisstudywasthechangefrombaselinetothe endofthe6-weektreatmentperiod intheTotalTicScore (TTS)oftheYaleGlobalTicSeverityScale(YGTSS).No significantdifferencewasfound inthetreatmenteffectson thechangefrombaselineinTTSforpatients treatedwith pramipexole and patients treated with placebo. Adverse reactions was reported in at least 5% of patients, and the adversereactionsprofilewasverysimilartowhatisknown from the use of pramipexoleinthemarketedindication in adults.TheCHMPsubsequentlyrecommendedandinclusion of this information in section 4.2 and 5.1of theSPC. |
| WS/0003 | This was an application for a variation following a worksharing procedure according to Article 20 of CommissionRegulation(EC)No1234/2008. UpdateoftheSPCfortheimmediaterelease formulationstoincludeinformationoneffectof                                                                                                                                                                                     | 22/04/2010 | 17/06/2010 | SmPC and PL | Based on the results of a long-term(26weeks) study in patients with idiopathic moderate to severe Restless Legs Syndrometoevaluateaugmentationandrebound,the CHMPconcluded that augmentation isseen,butisnot related to treatment with pramipexol. Rebound after abrupt discontinuation is seen in about 10% of patients. The CHMP                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

|         | abrupt discontinuation on worsening of symptom severity as compared to baseline (rebound) in sections 4.2 and5.1,updated informationregarding symptoms starting earlier than usual, be more intense and involve other limbs (augmentation) to reflect theresults of study248.629 in section 4.4 andinformationonlong-termefficacyinRestless Legs Syndrome (RLS) in section 5.1. C.I.3.b-Implementation of change(s)requested following the assessment of an USR, class labelling, a PSUR,RMP,FUM/SOï¼datasubmittedunderArticle 45/46,oramendmentstoreflectaCoreSPC- Change(s) with new additional data submitted by the MAH   |            |            |                        | also concluded that another important issue with pramipexol in RLS is low efficacy (although better then placebo).Basedon these conclusions theCHMP recommendedanupdateoftheSPCfortheimmediate release formulations for which RLS is indicated. In addition, the details of the local representatives for Bulgaria, Romania,Estonia andLithuaniainthepackageleafletwere updated for all presentations.   |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| X/0062  | AnnexI_2.(c) Change or addition of a new strength/potency                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 18/03/2010 | 10/06/2010 | Labelling and PL       |                                                                                                                                                                                                                                                                                                                                                                                                          |
| IA/0063 | IA_o7_a_Replacement/add.of manufacturing site: Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 01/12/2009 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                          |
| X/0059  | AnnexI_2.(d)Change or addition of a new pharmaceuticalform                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 25/06/2009 | 08/10/2009 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                          |
| I1/0060 | Update of section 4.8 of the SPC to include the terms 'dyspnoea'and'pneumonia'.ThePackageLeaflethas been updated accordingly. UpdateofSummaryofProductCharacteristics and PackageLeaflet                                                                                                                                                                                                                                                                                                                                                                                                                                     | 19/03/2009 | 17/04/2009 | SmPC and PL            | The MAH presented the results of pooled safety analyses of placebo-controlled clinical phaseII andphaseIIItrials in Parkinson's disease and Restless Legs Syndrome.The CHMPconsidered that,despitethefact that anassociation between the use of pramipexole and dyspnoea or pneumonia is not strictly proven, the tendencies and                                                                         |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |            |             | frequencies are sufficiently high to warrant an inclusion of both adverse events in the product information.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0056 | Updateofsection4.8oftheSPCwiththeterms compulsive shopping, vomiting, restlessness, amnesia, visual disturbance, hyperphagia, syncope andweight decrease.Thefrequencyforthe terms hypersexuality andpathologicalgamlinghas also been included.In addition,compulsiveshoppinghas been added to section 4.4 of the SPC. The PL is being updated accordingly. The local representative section has also been amended. UpdateofSummaryofProductCharacteristicsand Package Leaflet | 18/12/2008 | 26/01/2009 | SmPC and PL | FollowingtheCHMPassessmentofPSUR11,covering the period 7 0ctober 2007 to 6 April 2008 and including the analysis of spontaneously reported adverse events, clinical trial data andscientificliterature,theCHMPconcluded that theMAHshould includeadditionalAdverseDrugsReactions (ADRs)in the Summary ofProduct Characteristics(SPC). Basedonananalysisofthedataprovided,'compulsive shopping'ï¼'vomiting'ï¼'restlessness'ï¼'amnesia'ï¼'visual disturbance', 'hyperphagia', 'syncope' and 'weight decrease' havebeenintroducedtosection4.8of theSPC andsection 4of thePackageLeaflet.A shortdescriptive textofthe resultsfrom theDOMINIONstudywerealsoincluded in section4.8oftheSPC,includingthesuggestedriskfactors found and highlighting that the symptoms are seen with all typesofdopaminergictreatment. In addition, compulsive shopping has been added to section 4.4of theSPCassuggestedbytheCommitteeinthe assessment ofPSUR 11.ThePLwasbeingupdated accoOrdinglywiththenewADRs and in addition thelocal representativesectionwas amended. |
| IA/0058 | IA_o7_a_Replacement/add.ofmanufacturingsite: Secondarypackagingsite                                                                                                                                                                                                                                                                                                                                                                                                           | 04/09/2008 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| IA/0057 | IA_07_a_Replacement/add.ofmanufacturingsite: Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                                         | 04/09/2008 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| I1/0053 | Updateofsection4.8of theSPCandPL.                                                                                                                                                                                                                                                                                                                                                                                                                                             | 24/07/2008 | 03/09/2008 | SmPC and PL | TheMAHupdatedsection4.8of theSPC(undesirable                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

|         | Update of Summary of Product Characteristics and Package Leaflet                                                           |            |            |             | effects)toseparateAdverseDrugReactionsbyindication (Parkinson's disease and Restless LegsSyndrome).In addition otherminor amendmentshavebeen introduced throughout the product information.                                                                                                                                                                                                                                                 |
|---------|----------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0055 | IB_27_b_Change to testproc.ofimmediate packaging - other changes (incl. replacement/addition)                              | 14/07/2008 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| IA/0054 | IA_32_a_Change inbatch size of thefinishedproduct - up to 10-fold                                                          | 07/07/2008 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| N/0050  | Minor change in labelling or package leaflet not connected with theSPC(Art.61.3Notification)                               | 13/05/2008 | n/a        | PL          |                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| IB/0051 | IB_38_c_Change in test procedure of finished product - other changes                                                       | 15/04/2008 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| IA/0052 | IA_38_a_Change in test procedure of finished product - minor change to approved test procedure                             | 31/03/2008 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| II/0048 | Updateofsections4.4 and4.8of theSPCand relevantsection of thePL UpdateofSummaryofProductCharacteristicsand Package Leaflet | 24/01/2008 | 29/02/2008 | SmPC and PL | Followingtheevaluationof the9thPSURtheMAH was requested toupdateofsection4.8ofSPCandrelevant sectionsof thePL toreflecttheoccurrenceof hypersexuality and allergic reactions like hypersensitivity, rash and pruritus. Inaddition,theMAH amended theundesirableeffects frequencies for hypotension (low blood pressure), hallucinations, dizziness, abnormal dreams, insomnia and peripheral oedema (excess of fluid, usually in the legs). |

<div style=\"page-break-after: always\"></div>

| II/0049   | Updateoforchange(s)tothepharmaceutical documentation                                                                                                                                                                                    | 21/02/2008   | 26/02/2008   |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0047    | Renewalofthemarketing authorisation.                                                                                                                                                                                                    | 19/07/2007   | 17/09/2007   | SmPC, Annex I1, Labelling and PL | BasedontheCHMPreviewoftheavailableinformationand on the basis of a re-evaluation of the benefit risk balance, theCHMPisoftheopinionthatthequality,safety and efficacyof thismedicinalproductcontinues tobe adequatelyandsufficientlydemonstratedandtherefore consideredthatthebenefit/riskprofileofMirapexin continues tobefavourable.                                                                                                                                           |
| II/0040   | Updateof section4.4 and4.8ofSPC andrelevant section of the PL to reflect the occurrence of new advers events, including behavioural changes, hyperkinesiaandweightincrease. UpdateofSummaryofProductCharacteristics and Package Leaflet | 28/06/2006   | 04/08/2006   | SmPC and PL                      | Basedontheanalysisofspontaneouslyreportedadverse events, literature cases and clinical trials an emerging evidenceforacausalrelationshipbetweenabnormal dreams, abnormal behaviour, delusion, paranoia, increased eating, hyperkinesia, weight increase and pramipexole administration wasseen. Theundesirable effectssection hasbeenupdated toreflect these effects and a warning has been included to consider dosereductionortaperdiscontinuationifbehavioural changes occur. |
| IA/0046   | IA_08_a_Change in BR/QC testing - repl./add. of batch control/testing site                                                                                                                                                              | 16/06/2006   | n/a          |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| IA/0045   | IA_08_a_Change in BR/QC testing - repl./add. of batch control/testing site                                                                                                                                                              | 16/06/2006   | n/a          |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| IB/0044   | IB_38_c_Change in test procedure of finished product - other changes                                                                                                                                                                    | 11/05/2006   | n/a          |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

| IA/0043   | IA_o9_Deletionofmanufacturingsite                                                                                | 18/04/2006   | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                    |
|-----------|------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0042   | IA_08_a_Change in BR/QC testing - repl./add. of batch control/testing site                                       | 18/04/2006   | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                    |
| IA/0041   | IA_07_a_Replacement/add.of manufacturingsite: Secondary packaging site                                           | 18/04/2006   | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                    |
| I1/0036   | ExtensionofIndication                                                                                            | 23/02/2006   | 06/04/2006 | SmPC, Annex II and PL | Pleaserefer to theScientificDiscussion:MirapexinH-134- II-36-SD                                                                                                                                                                                                                                                                                                    |
| IB/0038   | IB_10_Minor change in the manufacturing process of the active substance                                          | 25/01/2006   | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                    |
| IA/0039   | IA_11_a_Change inbatch size of active substance or intermediate-upto10-fold                                      | 16/11/2005   | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                    |
| IA/0037   | IA_08_a_Change in BR/QC testing - repl./add. of batch control/testing site                                       | 21/10/2005   | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                    |
| II/0035   | Updateofsection4.8of theSPCandsection4ofthe PL. Update of Summary of Product Characteristics and Package Leaflet | 17/02/2005   | 29/03/2005 | SmPC and PL           | Section 4.8 of the SPC and the section 4 of the PL were updatedtoadd informationonthat,asdescribed inthe literature for dopamine agonists used for the treatment of Parkinson's disease,patients treated withpramipexole, especially at high doses, have been reported as showing pathological gambling,whichwasgenerallyreversible upon treatmentdiscontinuation. |
| II/0033   | Change(s) to the manufacturing process for the finished product                                                  | 17/02/2005   | 22/02/2005 |                       |                                                                                                                                                                                                                                                                                                                                                                    |
| II/0034   | Change(s) to container                                                                                           | 20/01/2005   | 27/01/2005 |                       |                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

| II/0032   | Updateofsection4.8oftheSPCandsection4of the PL. Update of Summary of Product Characteristics and Package Leaflet   | 16/09/2004   | 28/10/2004   | SmPC and PL SmPC, Labelling and PL   | The section 4.8 of the SPC and the section 4 of the PL were updated based on data from clinical trials and spontaneous reports in order to add information on an association betweenalteredlibidoincreaseordecrease)and pramipexoletreatment.                                                                                                                                                                                     |
|-----------|--------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| T/0029    | TransferofMarketingAuthorisation                                                                                   | 08/06/2004   | 22/07/2004   |                                      | TheEMEA,havingconsidered the application in accordance withCommissionRegulation(EC)No2141/96of7 November1996andhavingfound thatthedocuments submittedinsupportofsuchapplicationarecompleteand thatthepersontowhomthetransfershouldbegrantedis established within the European Economic Area, recommended the transferof theMarketingAuthorisation for the abovementionedmedicinalproducttoBoehringer IngelheimInternational GmbH. |
| IB/0030   | IB_14_a_Changeinmanuf.of active substance without Ph.Eur.certificate -change in manuf. site                        | 02/07/2004   | n/a          |                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| N/0031    | Minor changeinlabellingorpackageleafletnot connected with the SPC(Art.61.3 Notification)                           | 28/06/2004   | n/a          | PL                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| IB/0028   | IB_10_Minor change in the manufacturing process of the active substance                                            | 18/02/2004   | n/a          |                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| IB/0027   | IB_10_Minor change in the manufacturing process off theactivesubstance                                             | 18/02/2004   | n/a          |                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| IA/0026   | IA_11_a_Changeinbatch size of active substance or intermediate-upto10-fold                                         | 28/01/2004   | n/a          |                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

| IA/0025   | IA_o5_Change in the name and/or addressof a manufacturerof the finishedproduct                                                                                    | 19/01/2004   | n/a        | Annex II and PL                  |                                                                                                                                                                                                                                                                                                                                                             |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0024   | IA_o7_a_Replacement/add.of manufacturing site: Secondary packaging site IA_08_b_02_Change inBR/QC testing-repl./add. manuf. responsible for BR - incl. BC/testing | 22/10/2003   | n/a        | Annex II and PL                  |                                                                                                                                                                                                                                                                                                                                                             |
| IA/0023   | IA_01_Change in the name and/oraddress of the marketingauthorisationholder                                                                                        | 22/10/2003   | n/a        | SmPC, Labelling and PL           |                                                                                                                                                                                                                                                                                                                                                             |
| 1/0022    | 01_Withdrawal of themanufacturing authorisation for a site of manufacture                                                                                         | 02/09/2003   | 18/09/2003 |                                  |                                                                                                                                                                                                                                                                                                                                                             |
| 1/0021    | 01_Change in the name of a manufacturerof the medicinal product 11a_Changeinthenameofamanufacturerof the active substance                                         | 14/08/2003   | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                             |
| 1/0019    | 13_Batchsize ofactivesubstance                                                                                                                                    | 19/02/2003   | 04/03/2003 |                                  |                                                                                                                                                                                                                                                                                                                                                             |
| 1/0018    | 17_Changeinspecification of themedicinal product                                                                                                                  | 19/02/2003   | 04/03/2003 |                                  |                                                                                                                                                                                                                                                                                                                                                             |
| R/0017    | Renewal of the marketing authorisation.                                                                                                                           | 25/07/2002   | 08/11/2002 | SmPC, Annex I1, Labelling and PL | Following the CHMP Position statement on dopaminergic substances(CPMP/578/02,Rev1),information was includedontheassociationwithsomnolenceandepisodes ofsuddensleeponset,particularlyinpatientswith Parkinson's disease,thatsudden onsetofsleep during daily activities,insomecaseswithout awarenessorwarning signs,hasbeenreporteduncommonlyandthatpatients |

<div style=\"page-break-after: always\"></div>

|        |                                                                                                 |            |            | must be informed of this and advised to exercise caution while driving or operating machines during treatment with Mirapexin.Patientswhohaveexperiencedsomnolence and/oranepisodeofsuddensleeponsetmustrefrainfrom driving or operating machines and that a reduction of dosage or termination of therapy may be considered. TheCHMPwasof theopinionthatthequality,safetyand efficacyofthismedicinalproductcontinues tobe adequatelydemonstrated andthereforeconsideredby consensus that the benefit/risk profile of Mirapexin continuestobefavourablefor theindication\"Mirapexin tablets are indicated for treatment of the signs and symptoms of idiopathic Parkinson's disease, alone (without levodopa) or in combination with levodopa, i.e. over the course ofthedisease,throughtolatestageswhen the effectoflevodopawearsofforbecomesinconsistentand fluctuationsofthe therapeuticeffectoccur(endofdoseor   |
|--------|-------------------------------------------------------------------------------------------------|------------|------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1/0015 | 24_Change in testprocedure of active substance                                                  | 05/07/2002 | 09/07/2002 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 1/0014 | 20a_Extensionofshelf-lifeorretestperiodof the active substance                                  | 05/07/2002 | 09/07/2002 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 1/0013 | 14_Change in specifications of active substance 24_Change in test procedure of active substance | 05/07/2002 | 09/07/2002 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 1/0012 | 13_Batchsizeofactivesubstance                                                                   | 05/07/2002 | 09/07/2002 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 1/0011 | 12a_Changeinspecificationof starting material/intermediateusedinmanuf.oftheactive               | 05/07/2002 | 09/07/2002 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|         | substance                                                                                             |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|---------|-------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0010 | Updateofsection4.8oftheSPCfollowingPSUR 6. UpdateofSummaryofProductCharacteristicsand Package Leaflet | 17/01/2002 | 18/04/2002 | SmPC and PL | The adverse event\"confusion\"was added to the adverse eventshavingbeenreportedmorefrequentlyduringthe useofMirapexinthanunderplacebo.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| II/0007 | Extension of Indication                                                                               | 26/07/2001 | 21/10/2001 | SmPC and PL | The indication was extended to include treatment of early Parkinson's disease.In earlyPD,pramipexole delays the onsetoflatemotorcomplicationscomparedtolevodopa.In contrast,theaverageimprovementofmotorsymptomsis smallerwithpramipexole thanwithlevodopa.However, in 47%ofpramipexolepatientsthecontrolofmotor symptoms is still considered sufficient without supplementarylevodopa(compared to61%inthelevodopa group). The safety profile of pramipexole differed from that of levodopa(oedema andsomnolencebeing significantly more frequent during pramipexole treatment whereas dry mouth,sweating,dyskinesia/wearing off andconjunctivitis being significantly more frequent during levodopa treatment)but it is notevident whichsafetyprofileis the morefavourableone.Thesection4.1oftheSPCwas updated to extend the indication to the following: Mirapexin tablets are indicated for treatment of the signs and symptoms of idiopathic Parkinson's disease, alone (without levodopa)orin combinationwithlevodopa,i.e.over the courseofthedisease,through tolatestageswhen the effectoflevodopawearsofforbecomesinconsistentand fluctuationsofthe therapeuticeffectoccur(endofdose or \"on off\"fluctuations).Informationwas added tosection4.2 of the SPC regarding tapering off, as a slow tapering off |

<div style=\"page-break-after: always\"></div>

|         |                                                                           |            |            |                        | wouldintuitivelydecreasetheriskofNMS. In a post marketing interaction study with pramipexole and L-dopa reasonable reassurance was provided that pramipexole did not have any clinically relevant effect on the pharmacokinetics of levodopa in males and females. Consequently therespective warnings in section 4.5 of the SPCwereremoved.Insection5.1of theSPCwas updated toincludeinformation on that in acontrolled doubleblind clinical trial of 2-year duration, initial treatment with pramipexole significantly delayed the onset of motor complications, and reduced their occurrence compared to initial treatment with levodopa. Thi   |
|---------|---------------------------------------------------------------------------|------------|------------|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1/0009  | 03_Change in thename and/or addressof the marketing authorisation holder  | 14/09/2001 | n/a        | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 1/0008  | 01_Change following modification(s) of the manufacturing authorisation(s) | 14/09/2001 | n/a        | Annex II and PL        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 1/0006  | 20_Extension ofshelf-life asforeseen attime of authorisation              | 30/03/2001 | 02/04/2001 |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| II/0004 | UpdateofSummaryofProductCharacteristics                                   | 29/06/2000 | 20/10/2000 | SmPC                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 1/0005  | 20_Extensionofshelf-lifeasforeseen attimeof authorisation                 | 16/06/2000 | 27/07/2000 | SmPC                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| I1/0003 | Update of Summary of Product Characteristics and Package Leaflet          | 29/07/1999 | 29/11/1999 | SmPC and PL            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

| X-3-ii_Addition ofnewstrength                                                                   | 20/05/1999   | 26/10/1999   | SmPC, Annex II, Labelling and PL   | X/0002   |
|-------------------------------------------------------------------------------------------------|--------------|--------------|------------------------------------|----------|
| Minor change in labelling or package leaflet not connected with the SPC (Art.61.3 Notification) | 02/07/1998   | 16/09/1998   | Labelling and PL                   | N/0001   |